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Introduction: Acute liver failure (ALF) is a highly lethal disease, for which effective therapeutic methods are limited.
Although allogeneic liver transplantation is a viable treatment method for ALF, there is a serious shortage of liver
donors. Recent studies suggest that stem cell transplantation is a more promising alternative. Hence, we investigate
whether human adipose-derived stem cells (ASCs) have the therapeutic potential for ALF in this study based on the
studies of rat models.
Methods: Sprague Dawley rats were used to establish ALF models by D-galactosamine injection. These rats were
randomly divided into a human ASC-treated group and a phosphate-buffered saline (PBS) control group. The
human ASCs or PBS was transplanted through the spleen of rats. The indices of hepatic function and hepatic
histology were dynamically detected, and the survival rates of rats were also counted. Double-fluorescence
immunohistochemistry was employed to detect the ASC fate after transplantation. Moreover, both concentrated
ASC conditional media and ASC lysates were transplanted through the femoral vain of rats to investigate the
therapeutic potential for ALF.
Results: The ASC transplantation group showed improved viability in comparison with the sham control.
Histological and biochemical analysis suggested that liver morphology and function were improved in terms of
cell proliferation and apoptosis. Although a plethora of ASCs persist in the spleen, the improvement in liver
function was obvious. However, ASCs did not differentiate into hepatocytes after engrafting to livers within 3 days.
In addition, both concentrated serum-free ASC conditional media and ASC lysates, characterized by high levels of
hepatocyte growth factor and vascular endothelial growth factor, demonstrated obvious improvement in terms of
high survival rates of ALF rats.
Conclusion: Our data suggest that ASC transplantation has the potential for ALF treatment partly by the
mechanism of secreting growth factors contributing to liver regeneration.Introduction
Acute liver failure (ALF) is defined as the extensive ne-
crosis of hepatocytes caused by a variety of factors in a
short time, and severe hepatic disorders eventually may
lead to syndromes associating with functional failure
[1-3]. ALF is also characterized by acute progression and
high mortality, and effective treatments are still lacking.
Although common supportive treatment and artificial* Correspondence: qcfu85@163.com; xqliu2014@gmail.com
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unless otherwise stated.liver are accepted for clinic use, their efficacies remain
to be improved [4]. Liver transplantation shows rela-
tively good efficacy but its application is limited by both
the shortage of donor and expensive cost. Hepatocyte
transplantation has also been applied to elevate the sur-
vival rate of animals with ALF induced by chemistry and
surgery [5]. However, its clinical application was limited
for the availability of human hepatocytes and it remains
a challenge to amplify the primary hepatocytes after
cryopreservation and resuscitation [6,7]. Hence, it is ur-
gent to find alternative cell sources.
Stem cells represent a type of undifferentiated cells,
which could be expanded extensively in vitro [8]. Bone
marrow-derived mesenchymal stem cells (BMSCs) arehis is an Open Access article distributed under the terms of the Creative
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abilities of proliferation and differentiation, including
differentiating to hepatocyte-like cells [9-11]. Recently,
BMSC transplantation has shown therapeutic potentials
for liver failure in both rats and pigs [12,13]. Adipose-
derived stem cells (ASCs) are another important source
of adult stem cells [14-17]. Although BMSCs and ASCs
share similar properties, including cell surface markers,
gene expression profile, immunosuppressive properties,
and differentiation capacity, the proliferation rate of
ASCs is higher than that of BMSCs [18-22]. However,
extensive preclinical studies are needed to evaluate the
ASC treatment potential for liver failure.
In this study, human ASCs were transplanted through
the spleen to treat ALF rats. Biochemical indices of liver,
including serum albumin (ALB), alanine aminotransfer-
ase (ALT), aspartic aminotransferase (AST), hepatocyte
growth factor (HGF), vascular endothelial growth factor
(VEGF), liver histological changes, and survival rate,
were investigated to assess the efficacy of ASC treat-
ment. The distribution of ASCs in the main organs and
cell fate after transplantation were also detected. More-
over, both concentrated ASC conditional media and
ASC lysates were transplanted through the femoral vain
of rats to investigate the therapeutic potential for ALF.
The obtained data provided important information for
the potential application of ASC transplantation for ALF
treatment.
Methods
Animals and cell resources
Specific pathogen-free Sprague Dawley (SD) rats (male,
120 to 140 g) at the age of 4 to 6 weeks were provided
by SLAC Laboratory Animal Co., Ltd. (Shanghai, China)
(license #SCXK (Hu) 2007–0005). The rats were bred
within the Animal Unit of Tongji University. All experi-
ments involving animals were performed in accordance
with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals and approved by the
Biological Research Ethics Committee of the Chinese
Academy of Sciences. Human ASCs were prepared as pre-
viously described [23]. They were isolated from adipose
tissues obtained from patients undergoing tumescent lipo-
suction in accordance with procedures approved by the
Ethics Committee at the Chinese Academy of Medical Sci-
ences and Peking Union Medical College. All patients pro-
vided written informed consent. Briefly, adipose tissues
obtained from the patients were washed three times by
phosphate-buffered saline (PBS) with 1% penicillin/
streptomycin and carefully minced by sterile operation
scissors. The minced tissues were enzymatically dissoci-
ated for 45 minutes at 37°C by adding isometric 0.15%
collagenase type I (Gibco, now part of Thermo Fisher
Scientific, Waltham, MA, USA). The suspension wasneutralized with isometric culture media and centrifuged
at 500 g for 5 minutes. The cell pellet was resuspended in
Dulbecco’s modified Eagle’s medium/F12 (DMEM/F12)
media (Gibco) supplemented with 10% fetal bovine serum
(FBS) (Gibco) or 10% KnockOut Serum Replacement
(Invitrogen, now part of Thermo Fisher Scientific) or
ASC serum-free media (Advcell; BioWiseTech Co., Ltd.,
Wilmington, DE, USA) at a density of 2 × 106 cells/mL.
Cells were maintained at 37°C in a humidified incubator
supplemented with 5% CO2. Cells at passage 3 were
used for the following experiments.Detection of adipose tissue-derived stem cell surface
markers by using immunocytochemistry and flow
cytometry
For immunocytochemistry, cells were seeded into a sixwell
plate that was pre-coated with a cover glass. After 24 hours,
cells were fixed for 30 minutes by using 4% paraformalde-
hyde and incubated with CD29-FITC, CD44-PE, CD90-
FITC, CD105-PE, CD34-FITC, and CD133-PE anti-human
antibodies (0.5 μL/well) for 30 minutes. Cells were washed
by PBS for three times. The fluorescence was observed after
photophobical incubation for 30 minutes. For flow cytome-
try detection, the ASCs (passage 3) were used to prepare
single-cell suspension, and subsequently 2 μL of CD29-
FITC, CD44-PE, CD90-FITC, CD105-PE, CD34-FITC,
and CD133-PE antibodies were added into the suspension.
After incubating for 30 minutes photophobically, ASCs
were washed three times and detected by using a flow cy-
tometry (BD FACSAria III; BD Biosciences, San Jose, CA,
USA).Adipogenic, chondrogenic, and osteogenic differentiation
Human ASCs at a density of 5 × 103 cells/cm2 were
seeded into sixwell plates pre-coated with a cover glass.
The cells were induced for 3 weeks by using adipogenic
(#HUXMA-90031; Cyagen Biosciences Inc., Guangzhou,
China), chondrogenic (#HUXMA-90041; Cyagen Biosci-
ences Inc.), and osteogenic (#HUXMA-90021; Cyagen
Biosciences Inc.) differentiation media, respectively. Adi-
pocytes, chondrocytes, and osteocytes were observed by
using Oil Red O staining, Alcian blue staining, or Ali-
zarin red staining in accordance with the protocols of
the manufacturer (Cyagen Biosciences Inc.). Briefly, for
Oil Red O staining, cells were washed with PBS three
times and fixed with 4% formaldehyde for 10 minutes.
After incubation with Oil Red O reagent for 30 minutes,
cells were washed three times with PBS and observed by
using microscopy (IX71; Olympus, Tokyo, Japan). Simi-
larly, for Alcian blue staining and Alizarin red staining,
chondrocytes and osteocytes were fixed with 4% formal-
dehyde and incubated with Alcian blue reagent and Ali-
zarin red reagent for 3 hours and 30 minutes at room
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were removed by washing with PBS three times.
Intrasplenic adipose tissue-derived stem cell transplantation
Fifty male SD rats were intraperitoneally injected with
D-galactosamine (D-gal) at a dose of 1.4 g/kg. Thirty
rats with ALF were randomly divided into an ASC treat-
ment group and a PBS treatment group. The transverse
incision of about 1 cm was obtained at the right subcos-
tal of rats in a laminar flow cabinet on the next day of
modeling. The spleen was exposed by using a smooth
forceps, and 100 μL of ASC suspension (5 × 106 cells)
was injected into the spleen. The control group was
injected with 100 μL of PBS. Then local hemostasis and
wound suturation were performed. The body weight, ac-
tivity, food intake, urine, hair color, muscle strength,
and response to stimuli of rats were daily observed and
recorded, and the survival rates were statistically ana-
lyzed. The tail blood of rats was obtained at different
time points (1, 3, and 7 days after D-gal injection).
Serum ALT, AST, and ALB levels were detected by using
an automatic biochemical analyzer. The left hepatic
lobes were obtained once the rats died or were sacri-
ficed 7 days later after D-gal injection, and the paraffin-
embedded sections of the livers were further obtained.
The histological changes were observed at high magnifi-
cation after hematoxylin-and-eosin (HE) staining. Ki67
staining and the terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) assay were used to
detect cell proliferation and apoptosis, respectively.
Tracing of transplanted human adipose tissue-derived
stem cells
Human ASCs at passage 3 were infected with lentivirus
expressing ZsGreen at 70% cell confluence [24]. The in-
fection efficiency was observed after 48 hours of infection
by using a fluorescence microscope (IX71; Olympus), and
the cells were cultured successively. Twenty ALF model
rats were randomly divided into the intrasplenic trans-
plantation group and the vein transplantation group, and
these rats were injected with 5 × 106 ASCs via the spleen
and femoral vein, respectively. The distribution and engraf-
tation of ASCs in organs were dynamically detected by
using immunohistochemistry. Human ALB and human
alpha-fetoprotein in the ZsGreen-positive ASCs were de-
tected by using double-fluorescence immunohistochemistry
analysis. The antibodies specific against ZsGreen, human
ALB, and human alpha-fetoprotein were purchased from
Abcam Ltd. (Cambridge, UK).
Intravenous concentrated adipose tissue-derived stem cell
(ASC) conditional media/ASC lysate injection
For preparation of ASC conditional media, 106 human
ASCs were seeded into a T75 culture flask, and themedia were replaced with 7 mL of DMEM/F12 media
(without FBS) 12 hours later. The supernatant was col-
lected after 24 hours of incubation. The ASC conditional
media were concentrated 25 times by centrifugation at
8,000 g per minute by using ultrafiltration centrifugal
tubes (MWCO:3 K; Sartorius, Goettingen, Germany).
For preparation of ASC lysates, 107 ASCs were collected
in a 15-mL tube. The cells were frozen at −80°C and
thawed at 37°C three times. Then 1 mL of DMEM/F12
media (without FBS) was added into the tube. After vor-
tex for 1 minute, the supernatant was collected by cen-
trifugation at 5,000 g for 5 minutes. The collected
supernatant was filtrated by a 0.22-μm filter (Millipore,
Billerica, MA, USA), and each rat was injected with
100 μL via the femoral vein. The blood of rats was har-
vested after 3 days of injection, and the serum was col-
lected by centrifugation at 4°C. The levels of HGF and
VEGF in the serum, concentrated ASC conditional media,
and ASC lysates were detected by using an enzyme-linked
immunosorbent assay (ELISA) kit (Shanghai ExCell
Biology, Inc., Shanghai, China) in accordance with prod-
uct instruction manuals.Statistical analysis
Data were represented as mean ± standard error of mean.
Survival rate was analyzed by using Kaplan-Meier analysis.
Data were analyzed by using Statistical Product and
Service Solutions (SPSS) version 19.0 (SPSS, Inc., Chicago,
IL, USA).Results
Characterization of adipose tissue-derived stem cells for
transplantation
The morphology of expanded human ASCs appeared to
be fibroblast-like and shuttle-shaped. To trace the dis-
tribution of transplanted ASCs in the ALF rats, we
employed the lentivirus expressing ZsGreen to infect
human ASCs. Transplanted ASCs and their correspond-
ing progenies were traced by using a fluorescence
microscope at 488 nm, and the labeling efficiency was
over 90% (Figure 1A). CD29, CD44, CD90, and CD105
were highly expressed, whereas the cells expressed with
minimal levels of CD34 and CD133 (Figure 1B). Fur-
thermore, flow cytometry revealed that over 90% cells
expressed CD29 (92.9%), CD44 (97.5%), CD90 (97.1%),
and CD105 (97.5%) but that almost all of the cells were
negative for CD34 (0.5%) and CD133 (0%) (Figure 1C).
To definitely characterize the multipotency of human
ASCs, we performed triplet differentiation assay, con-
sisting of adipogenic differentiation, chondrogenic
differentiation, and osteogenic differentiation. Triplet
differentiation assay indicated that the multipotency of
cultured ASCs was well maintained (Figure 1D).
Figure 1 (See legend on next page.)
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Figure 1 Characterization of human adipose tissue-derived stem cells (ASCs). (A) Morphology of ZsGreen-positive ASCs was observed under
bright-field and green fluorescence. (B) Immunostaining indicated that ASCs were positive for cell surface markers CD29, CD44, CD90, and CD105
and negative for CD34 and CD133. (C) Flow cytometry confirmed that the cells were negative for CD34 and CD133 but that CD29, CD44, CD90,
and CD105 were highly expressed. (D) Triplet differentiation assays revealed that ASCs could differentiate into adipocytes, chondrocytes, and
osteocytes. Adipocytes, chondrocytes, and osteocytes were stained by Oil Red O, Alcian blue 8GX, and Alizarin red, respectively.
DAPI, 4′,6-diamidino-2-phenylindole.
Chen et al. Stem Cell Research & Therapy  (2015) 6:40 Page 5 of 11The survival rate and biochemical indicator analysis after
adipose tissue-derived stem cell treatment
D-gal is known for inducing the features of acute hepa-
titis through affecting cell membranes and the synthesis
of nucleic acids and proteins and has been used exten-
sively in the development of animal models of ALF
[25,26]. Human ASCs were transplanted into spleens of
rats 24 hours later after D-Gal injection. All of the ani-
mals were followed up for 7 days after transplantation,
and the percentage of animals that survived was ana-
lyzed. On the first day after transplantation, 100% (15
out of 15) and 86.7% (13 out of 15) of the animals sur-
vived in the ASC-treated group and PBS-treated group,
respectively. On the second day after treatment, theFigure 2 The survival rate and biochemical indices after adipose tissu
D-galactosamine (D-gal) induced acute liver failure in the ASC-treated grou
rate of the ASC-treated group at each time point was prolonged significan
significant difference of serum albumin (ALB) levels was observed between
The serum alanine aminotransferase (ALT) level of the ASC treatment group
PBS-treated group (506.7 ± 166 U/L; 112.5 ± 55.4 U/L) at 1 and 3 days, indic
aspartic aminotransferase (AST) level of the ASC-treated group (1,186.7 ± 42
PBS-treated group (2,396.7 ± 743 U/L; 321.3 ± 185.7 U/L) at 1 and 3 days (nsurvival rate of the PBS-treated group decreased to
33.3% (5 out of 15), whereas the survival rate of the
ASC-treated group was 53.3% (8 out of 15). After
48 hours, the survival rates of both groups remained the
same as the second day after treatment (Figure 2A). In
addition, the rats in the PBS-treated group were charac-
terized by aberrant listlessness, lethargy, refusal to eat,
and messy hair, whereas the ASC-treated group exhib-
ited a better spirit and the total mortality was 46.7%,
suggesting that ASC treatment promoted the viability of
ALF rats. We next measured the biochemical indices of
both groups to determine whether ASC treatment could
improve liver function of ALF rats. Serum ALB levels of
both groups decreased obviously within 2 days ande-derived stem cell (ASC) treatment. (A) Survival curves of
p and the phosphate-buffered saline (PBS)-treated group. The survival
tly compared with the PBS-treated group (n = 15, P <0.05). (B) No
the PBS-treated group and the ASC-treated group (n = 5, P >0.05). (C)
(301.7 ± 116 U/L; 47 ± 9.1 U/L) was significantly lower than that of the
ative of liver function improvement (n = 5, P <0.01). (D) The serum
6.2 U/L; 128 ± 19.3 U/L) was significantly lower than that of the
= 5, P <0.01).
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jection. However, there was no significant difference be-
tween the ASC-treated group and the PBS-treated
group (Figure 2B). The ALT and AST levels of the
PBS-treated group increased to the maximum values
after D-gal injection whereas those of the ASC-treated
group were obviously lower. Serum ALT and AST
levels in both groups were markedly decreased after
3 days of ASC transplantation; however, those of the
ASC-treated group were lower than those of the PBS-
treated group, indicative of liver function improve-
ment. Serum ALT and AST levels of both groups
returned to normal 7 days later (Figure 2C-D).Figure 3 Liver morphology, cell proliferation, and apoptosis after adi
morphology of normal rats, D-galactosamine (D-gal) induced rats, phospha
hematoxylin-and-eosin staining sections of normal rats, D-gal induced rats,
showed significant morphologic improvement compared with PBS-treated
liver sections. The ASC-treated group showed more positive cells (black arr
promoted cell proliferation in liver. (D) Quantification analysis of the Ki-67 s
arrow) were observed in the untreated group by TUNEL (terminal deoxynu
were observed in the ASC-treated group and normal livers, indicating that
of TUNEL-positive cells in the field of view (FOV) by digital image analysis.Effects of adipose tissue-derived stem cell treatment on
cell proliferation and apoptosis
The morphology of hepatic tissues was obviously changed
after D-gal injection compared with normal liver, given
that point or flake congestion was observed on the surface
of liver, and the liver was enveloped with a strained
and dull capsule. Three days after transplantation, the
livers of the PBS-treated group presented ischemic ne-
crosis whereas the ASC-treated group appeared normal
(Figure 3A). Correspondingly, HE staining showed that
the livers of the PBS-treated group had disorganization of
hepatic lobules, hepatic cord disorders, extensive necrosis
of hepatocytes, and sinusoidal dilatation. Additionally, thepose tissue-derived stem cell (ASC) treatment. (A) Liver
te-buffered saline (PBS)-treated rats, and ASC-treated rats. (B) Liver
PBS-treated rats, and ASC-treated rats. The livers of ASC-treated rats
rats. (C) Positive cells were observed by Ki-67 staining (brown) in the
ows) than the PBS-treated group, suggesting that ASC treatment
taining section by Image-Pro Plus software. (E) Apoptotic cells (black
cleotidyl transferase dUTP nick end labeling) assay. Few apoptotic cells
ASC treatment protected liver cells from apoptosis. (F) Quantification
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treated group contained a plethora of inflammatory cell
infiltrations. However, the structure of hepatic tissues in
the ASC-treated group appeared normal, suggesting that
the liver functional indices of the ASC-treated group were
significantly improved (Figure 3B). Given that the prolifer-
ation of hepatocytes may contribute to the functional
improvement of the injured livers, we next investigated
whether the ASC transplantation led to liver cell prolifera-
tion by Ki-67 stain. Proliferative cells were distributed par-
ticularly around the central vein in the hepatic tissues of
the ASC-treated group but not in the PBS-treated group,
indicative of the hepatocytic proliferation (Figure 3C).
Moreover, quantification analysis revealed that ap-
proximately 30% of proliferative cells were increased in
the ASC-treated group compared with the PBS group
(Figure 3D). To determine whether ASC treatment re-
duced the number of apoptotic cells, TUNEL assays
were used. The liver section of the PBS-treated group
was characterized by apoptotic nuclei cells, indicative
of hepatocytic apoptosis. In contrast, few apoptotic
cells were found in the ASC-treated group, demon-
strating that ASC transplantation protected liver cells
from apoptosis (Figure 3E). Quantification analysis fur-
ther revealed that over 20% of apoptotic cells were re-
duced in the ASC-treated group compared with the
PBS-treated group (Figure 3F).
Cell fate after transplantation
Several delivery methods had been used to transplant
cells through peripheral vein, hepatic artery, portal vein,
liver, and spleen. To monitor the fate of transplanted
cells, we employed the ASCs infected with lentivirus ex-
pression ZsGreen to transplant through the spleen and
femoral vein. Interestingly, we found that femoral vein
delivery showed a higher engraftation rate to the liver
than spleen delivery. More ZsGreen-positive cells were
observed in the spleen through spleen delivery than
intravenous transplantation, suggestive of a plethora of
transplanted cells remaining in the spleen. Moreover, a
few ASCs migrated to the lung via spleen delivery and
showed a similar distribution pattern compared with
femoral vein delivery. Of note, there were no trans-
planted cells engrafting to the heart and kidney in either
delivery method. In short, after injection in the spleen
and femoral vein, ZsGreen-positive cells were observed
in the liver after 24 hours of transplantation, suggesting
that transplanted cells could rapidly reach the injury
hepatic tissues (Figure 4A). To assess whether the trans-
planted ASCs differentiated into hepatocytes, we investigated
the coexpression of ZsGreen and markers of human hepato-
cytes, including human ALB and human alpha-fetoprotein.
Double-fluorescence immunohistochemistry analysis found
no expression of either ALB or alpha-fetoprotein inZsGreen-positive cells within 3 days after transplantation,
indicating that the transplanted ASCs did not differentiate
into hepatocytes in the short term (Figure 4B).
Effects of adipose tissue-derived stem cell (ASC) conditional
media and ASC lysate on acute liver failure rats
By ELISA, both HGF and VEGF were accumulated in cul-
ture supernatant, cell lysates, and ASC conditional media
after 24 hours, suggesting that transplanted ASCs secreted
significant amounts of HGF and VEGF (Figure 5A, B).
Owing to the high levels of HGF and VEGF secreted by
ASCs, we next investigated whether ASC culture
supernatant, ASC lysates, or concentrated ASC condi-
tional media had a therapeutic effect on ALF. Interest-
ingly, the survival rate of both the ASC lysate-treated
group and the ASC conditional medium-treated group
was obviously higher than that of the PBS-treated
group (Figure 5C). After 3 days of transplantation,
VEGF level did not show any difference between each
group whereas the HGF levels in both groups were sig-
nificantly increased, indicating that both ASC lysate
and ASC conditional media markedly upregulated
serum HGF level, associating with the restoration of
liver function (Figure 5D, E).
Discussion
Stem cells are characterized by their ability to undergo
self-renewal and multilineage differentiation and to form
terminally differentiated cells under appropriate condi-
tions [27]. Ideal stem cell types for clinical use should
meet the following set of four criteria: (1) efficacy, (2)
abundance, (3) minimal invasion, and (4) safety [28]. Al-
though BMSCs are considered a benchmark for clinic
purposes, BMSC isolation involves an invasive and pain-
ful procedure characterized by low yield [29-31]. On the
other hand, ASCs have the potentials to differentiate to
chondrocytes, adipocytes, neuron-like cells, and liver-
like cells [32,33]. They show strong proliferation ability
and present low immunogenicity [34,35]. Furthermore,
ASCs appear to be more genetically stable in long-term
culture compared with BMSCs [36,37]. Moreover, ASCs
can be easily isolated and effectively expanded in vitro
with intact multipotency under appropriate culture con-
ditions. Recent studies have shown that ASC transplant-
ation displays good therapeutic efficacy on multiple
diseases, including liver failure [38]. Herein, our data
have demonstrated that human ASC transplantation
could efficiently improve the liver function of ALF rats.
Although we used human ASCs to transplant into im-
munocompetent rats instead of immonodeficient recipi-
ents, the human ASCs indeed increased the survival rates
of the immunocompetent ALF rats. Many other groups
had reported that they had successfully transplanted hu-
man cells, including human mesenchymal stem cells and
Figure 4 The cell fate of transplanted adipose tissue-derived stem cells (ASCs) in the liver. (A) Cell tracing after transplantation.
Distribution of transplanted ZsGreen-positive cells were found in the liver, spleen, lung, heart, and kidney after delivery through the spleen or
femoral vein. More positive cells (black arrow) were observed in the livers of rats 24 hours after intravenous ASC transplantation through the
spleen, indicating that the migration rate to the liver was higher through intravenous transplantation. Moreover, a plethora of transplanted cells
persisted in the spleen through spleen delivery. Positive cells were observed in the lung but not in the heart and kidney. (B) Double-fluorescence
imaging revealed that there was no human albumin (red) or human alpha-fetoprotein (red) expression in the livers, suggesting that transplanted
ASCs did not differentiate into hepatocytes. AFP, alpha-fetoprotein; ALB, albumin; DAPI, 4′,6-diamidino-2-phenylindole.
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hosts and obtained functional outcomes [39-41].
In the present study, although only a few cells migrated
to the liver via spleen delivery and most transplanted cells
remained in the spleen, ASC treatment indeed attenuated
the ALF conditions. Moreover, the therapeutic efficacy
was noticeable although the transplanted ASCs did not
differentiate into hepatocytes in the injury liver within a
short term. Based on these data, we hypothesize that ASC
may promote hepatocytic proliferation and inhibit cells
apoptosis, resulting in a restoration of liver function by
the likelihood of secreting growth factors. Indeed, cyto-
kines secreted by stem cells may play important roles in
the regulation of organ function [42,43]. Recent studies
have revealed that serum aminotransferase level was sig-
nificantly decreased by treatment with MSC conditional
media, suggesting that factors secreted from stem cellsmay improve liver function and increase the survival rate
of rats with hepatic failure [44]. It has also been docu-
mented that the conditional media of liver stem cells dis-
tinctly increase the survival rate, promote hepatocytic
proliferation, and inhibit hepatocyte apoptosis in treating
fulminant hepatic failure in mice [45]. Umbilical cord
mesenchymal stem cells have shown a strong ability to
promote the regeneration of autologous hepatocytes using
a paracrine approach instead of adult hepatocytes [46]. In
this study, both ASC lysate and ASC conditional media
have demonstrated better therapeutic potential in ALF
treatment. Although the VEGF level did not markedly
change, the increment of the HGF level was significantly
increased in the serum of the ASC-treated group, support-
ing a view that ASC transplantation may attenuate the
ALF conditions by secreting factors valuable to liver func-
tion improvement.
Figure 5 Levels of key growth factors for liver function. (A) The hepatocyte growth factor (HGF) levels were determined by enzyme-linked
immunosorbent assay (ELISA) in Dulbecco’s modified Eagle’s medium/F12 (DMEM/F12), adipose tissue-derived stem cell (ASC) serum-free culture
cell supernatant (supernatant), ASC lysate, and concentrated ASC conditional media (CM) (n = 3). (B) The vascular endothelial growth factor (VEGF)
levels were determined by ELISA in DMEM/F12, ASC serum-free culture cell supernatant (Supernatant), ASC lysate (Lysate), and concentrated ASC
CM (n = 3). (C) Survival curve of the DMEM/F12 group (Control), the ASC lysate group (Lysate), and the concentrated ASC CM group. The survival
rate of the ASC lysate-treated group and the CM-treated group was significantly higher, implying that factors secreted by ASCs may play key roles
in liver failure improvement (phosphate-buffered saline group: n = 8; ASC lysate/CM group: n = 9; P <0.01). (D) Serum HGF level of the DMEM/F12
group (Control), the ASC lysate group (Lysate), the ASC transplantation group (ASC), and the concentrated ASC CM group (n = 5). (E) Serum VEGF
level of rats after treatment (n = 5). *P <0.05, **P <0.01.
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higher in the serum of the PBS-treated control group
than that of the ASC-, lysate-, and conditional media-
treated groups at day 1. One possible reason might be
that the bodies of the rats have protective effects against
the sudden or acute injury through rapidly increasing
the levels of growth factors. Particularly, HGF is an im-
portant growth factor for the proliferation of hepato-
cytes. The rapidly increasing HGF levels can compensate
the injury of the livers by D-gal. In the ASC, lysate, and
conditional media treatment groups, because these fac-
tors (ASCs, lysates, and conditional media) might offset
the protective effects of the bodies, the levels of HGF
and VEGF were much lower than those of the control
groups. Other groups had reported similar protective ef-
fects in injury. It was reported that HGF levels increased
rapidly after ischemia/reperfusion injury [47]. Circulat-
ing HGF increased in the early stage of acute myocardial
infarction [48]. Moreover, it had been found that HGF
was upregulated in the injury liver following CCl4 ad-
ministration [49].Conclusions
Our studies have revealed that ASC treatment signifi-
cantly improves liver function in terms of survival rates
in accordance with a better hepatic tissue morphology
and biochemical indices. In summary, ASC transplant-
ation may have a better potential for ALF treatment.
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